Compare CRDL & NCSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRDL | NCSM |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oilfield Services/Equipment |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.3M | 97.3M |
| IPO Year | N/A | 2017 |
| Metric | CRDL | NCSM |
|---|---|---|
| Price | $1.07 | $39.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 373.9K | 7.8K |
| Earning Date | 03-30-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.53 |
| Revenue | N/A | ★ $178,000,000.00 |
| Revenue This Year | N/A | $11.25 |
| Revenue Next Year | N/A | $7.76 |
| P/E Ratio | ★ N/A | $8.66 |
| Revenue Growth | N/A | ★ 16.49 |
| 52 Week Low | $0.77 | $23.89 |
| 52 Week High | $1.59 | $53.69 |
| Indicator | CRDL | NCSM |
|---|---|---|
| Relative Strength Index (RSI) | 57.74 | 53.27 |
| Support Level | $0.95 | $36.03 |
| Resistance Level | $1.04 | $40.63 |
| Average True Range (ATR) | 0.05 | 1.70 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 76.47 | 71.04 |
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completions and field development strategies. NCS provides its products and services to exploration and production companies for use in onshore wells, predominantly wells that have been drilled with horizontal laterals in unconventional oil and natural gas formations. The company's offering is its fracturing systems products and services, which enable efficient pinpoint stimulation: the process of individually stimulating each entry point into a formation targeted by an oil or natural gas well. It sell products and services in North America and in selected international markets.